1
Camellia W Adams, Leonard G Presta, Mark Sliwkowski: Treatment with anti-ErbB2 antibodies and chemotherapeutic agents. Genentech, Wendy M Lee, February 3, 2009: US07485302 (50 worldwide citation)

The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and chemotherapeutic agents.


2
Camellia W Adams, Andrew C Chan, Craig W Crowley, Henry B Lowman, Gerald R Nakamura, Leonard G Presta: Immunoglobulin variants and uses thereof. Genentech, Morrison & Foerster, September 21, 2010: US07799900 (39 worldwide citation)

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.


3
Camellia W Adams, Andrew C Chan, Craig W Crowley, Henry B Lowman, Gerald R Nakamura, Leonard G Presta: Immunoglobulin variants and uses thereof. Genentech, Morrison & Foerster, October 22, 2013: US08562992 (33 worldwide citation)

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.


4
Camellia W Adams, Paul J Carter, Brian M Fendly, Austin L Gurney: Agonist antibodies. Genentech, Steven B Kelber, Piper Marbury Rudnick & Wolfe, January 29, 2002: US06342220 (30 worldwide citation)

Various forms of c-mpl agonist antibodies are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.


5
Camellia W Adams, Leonard G Presta, Mark Sliwkowski: Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies. Genentech, Wendy M Lee, May 26, 2009: US07537931 (27 worldwide citation)

The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.


6
Camellia W Adams, Leonard G Presta, Mark Sliwkowski: Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies. Genentech, Wendy M Lee, January 4, 2011: US07862817 (23 worldwide citation)

The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.


7
Camellia W Adams, Napoleone Ferrara, Ellen H Filvaroff, Weiguang Mao, Leonard G Presta, Max L Tejada: Humanized anti-TGF-beta antibodies. Genentech, Gates & Cooper, May 5, 2009: US07527791 (23 worldwide citation)

Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.


8
Camellia W Adams, Leonard G Presta, Mark Sliwkowski: Treatment with anti-ErbB2 antibody combinations. Genentech, Wendy M Lee, Atulya R Agarwal, March 10, 2009: US07501122 (23 worldwide citation)

The present application describes methods for treating ErbB-expressing cancer with anti-ErbB2 antibody combinations.


9
Camellia W Adams, Leonard G Presta, Mark Sliwkowski: Treatment with anti-ErbB2 antibodies and anti-hormonal compounds. Genetech, Wendy M Lee, March 3, 2009: US07498030 (19 worldwide citation)

The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and anti-hormonal compounds, such as anti-estrogens.


10
Camellia W Adams, Avi J Ashkenazi: Nucleic acid encoding DR5 antibodies and uses thereof. Genentech, Arnold & Porter, Diane Marschang, Ginger R Dreger, October 4, 2011: US08030023 (17 worldwide citation)

The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.